CRDF CARDIFF ONCOLOGY INC

Ownership history in UBS Group AG  ·  28 quarters on record

This page tracks every 13F SEC filing in which UBS Group AG reported a position in CARDIFF ONCOLOGY INC (CRDF). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 87,429 -118,746 -57.6% 0.00% $246K $2.81
2025 Q3 REDUCED 206,175 -426,825 -67.4% 0.00% $425K $2.06
2025 Q3 ADDED 633,000 +435,562 +220.6% 0.00% $1.3M $2.06
2025 Q2 REDUCED 197,438 -435,562 -68.8% 0.00% $622K $3.15
2025 Q2 ADDED 633,000 +546,465 +631.5% 0.00% $2.0M $3.15
2025 Q1 REDUCED 86,535 -546,465 -86.3% 0.00% $272K $3.14
2025 Q1 ADDED 633,000 +603,000 +2010.0% 0.00% $2.0M $3.14
2024 Q4 REDUCED 30,000 -603,000 -95.3% 0.00% $130K $4.34
2024 Q4 ADDED 633,000 +349,648 +123.4% 0.00% $2.7M $4.34
2024 Q4 ADDED 283,352 +234,788 +483.5% 0.00% $1.2M $4.34
18 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CRDF price (monthly, adj. close)
← Back to UBS Group AG Holdings